NYLIM
ARCT icon

New York Life Investment Management’s Arcturus Therapeutics ARCT Stock Holding History

New York Life Investment Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,040
Closed -$357K – 1211
2022
Q4 		$357K Buy
21,040
+2,371
+13% +$41.3K ﹤0.01% 1086
2022
Q3 		$277K Buy
18,669
+1,372
+8% +$23K ﹤0.01% 1122
2022
Q2 		$272K Buy
+17,297
New +$339K ﹤0.01% 1178

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

New York Life Investment Management's ARCT Position: Q1 2023 in Review

New York Life Investment Management sold out of Arcturus Therapeutics (ARCT) in Q1 2023, closing a stake of 21,040 shares — an estimated $357K sold.

New York Life Investment Management first reported a position in ARCT in Q2 2022 and held it in 3 quarters. The position peaked at $357K in Q4 2022. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2023.

  • New York Life Investment Management reported no remaining Arcturus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • New York Life Investment Management sold 21,040 Arcturus Therapeutics shares in Q1 2023, an estimated $357K.
  • New York Life Investment Management first reported a position in Arcturus Therapeutics in Q2 2022 and held it in 3 quarters.
  • New York Life Investment Management's Arcturus Therapeutics position peaked at $357K in Q4 2022.
  • 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.